| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3849967 | American Journal of Kidney Diseases | 2011 | 4 Pages |
Abstract
Pemetrexed is an antifolate agent approved for the treatment of advanced lung cancer. Major side effects include myelosuppression and neutropenia. Three patients developed kidney disease while being treated with maintenance pemetrexed. Kidney biopsy specimens showed tubulointerstitial injury with tubular simplification, shrinkage, loss of brush border, and tubular atrophy in a more advanced case. Kidney function remained impaired, but stable, after discontinuation of pemetrexed therapy in all cases.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ilya G. MD, M. Catherine MD, Vincent MD, Surya V. MB,BS,